Louise Chen
Stock Analyst at Scotiabank
(3.28)
# 1,018
Out of 5,140 analysts
297
Total ratings
47.33%
Success rate
2.34%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Sector Outperform | $35 → $40 | $34.22 | +16.89% | 5 | Jan 29, 2026 | |
| JNJ Johnson & Johnson | Maintains: Sector Outperform | $230 → $265 | $242.49 | +9.28% | 41 | Jan 22, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Sector Perform | $53 → $60 | $60.66 | -1.09% | 2 | Jan 9, 2026 | |
| MRK Merck & Co. | Maintains: Sector Outperform | $105 → $120 | $122.26 | -1.85% | 26 | Dec 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $650 → $770 | $779.67 | -1.24% | 2 | Nov 24, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $18.88 | +323.73% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $3.24 | +177.78% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $29.31 | -52.23% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.94 | +518.56% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $23.39 | +135.14% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Perform | $55 | $70.66 | -22.16% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $5.65 | +165.49% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $85.66 | -41.63% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $5.73 | +161.78% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $37.34 | -54.47% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $72.86 | -3.93% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $14.88 | +236.02% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $9.00 | +233.33% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $20.04 | +174.45% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.30 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $47.42 | +237.41% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $58.51 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $224.81 | +6.76% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $26.65 | +68.86% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.80 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $27.15 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $1,009.52 | -12.33% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.37 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $26.60 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.88 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.45 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.21 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.92 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.59 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.65 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.78 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.78 | +1,619.58% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.65 | +88.68% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $15.29 | +227.01% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $25.42 | +96.73% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.30 | +117.39% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.59 | +1,413.11% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $0.61 | +277,093,496.06% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $195.05 | +32.27% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.18 | +4,137.29% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.20 | +1,566.67% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $8.50 | +429.41% | 1 | Jun 22, 2017 |
Teva Pharmaceutical Industries
Jan 29, 2026
Maintains: Sector Outperform
Price Target: $35 → $40
Current: $34.22
Upside: +16.89%
Johnson & Johnson
Jan 22, 2026
Maintains: Sector Outperform
Price Target: $230 → $265
Current: $242.49
Upside: +9.28%
Bristol-Myers Squibb Company
Jan 9, 2026
Maintains: Sector Perform
Price Target: $53 → $60
Current: $60.66
Upside: -1.09%
Merck & Co.
Dec 4, 2025
Maintains: Sector Outperform
Price Target: $105 → $120
Current: $122.26
Upside: -1.85%
Regeneron Pharmaceuticals
Nov 24, 2025
Maintains: Sector Perform
Price Target: $650 → $770
Current: $779.67
Upside: -1.24%
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $18.88
Upside: +323.73%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $3.24
Upside: +177.78%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $29.31
Upside: -52.23%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.94
Upside: +518.56%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $23.39
Upside: +135.14%
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $70.66
Upside: -22.16%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $5.65
Upside: +165.49%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $85.66
Upside: -41.63%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $5.73
Upside: +161.78%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $37.34
Upside: -54.47%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $72.86
Upside: -3.93%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $14.88
Upside: +236.02%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $9.00
Upside: +233.33%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $20.04
Upside: +174.45%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.30
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $47.42
Upside: +237.41%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $58.51
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $224.81
Upside: +6.76%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $26.65
Upside: +68.86%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.80
Upside: -
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $27.15
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $1,009.52
Upside: -12.33%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.37
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $26.60
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.88
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.45
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.21
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.92
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.59
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.65
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.78
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.78
Upside: +1,619.58%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.65
Upside: +88.68%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $15.29
Upside: +227.01%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $25.42
Upside: +96.73%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $2.30
Upside: +117.39%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.59
Upside: +1,413.11%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $0.61
Upside: +277,093,496.06%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $195.05
Upside: +32.27%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.18
Upside: +4,137.29%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.20
Upside: +1,566.67%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $8.50
Upside: +429.41%